Understanding the Potential Promise and Pitfalls of Intravenous Gentamicin as a Therapy for Epidermolysis Bullosa

JAMA Dermatol. 2022 Apr 1;158(4):356-358. doi: 10.1001/jamadermatol.2021.5630.

Authors

Maria C Bolling¹, Cristina Has², Anna L Bruckner³

Affiliations

¹ Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
² Department of Dermatology, Medical Center - University of Freiburg, Freiburg, Germany.
³ Departments of Dermatology and Pediatrics, University of Colorado School of Medicine, Aurora.

PMID: 35234816
DOI: 10.1001/jamadermatol.2021.5630

No abstract available

Publication types

Comment

MeSH terms

Administration, Intravenous
Epidermolysis Bullosa* / drug therapy
Gentamicins* / adverse effects
Humans
Wound Healing

Substances

Gentamicins